Peer Reviewed

1

Document Type

Article

Publication Date

26-1-2018

Keywords

bcl2-Associated X Protein, colorectal cancer

Funder/Sponsor

Science Foundation Ireland (13/IA/ 1881 and 15/ERA-CSM/3268) and Health Research Board (HRA-POR-2015-1091)

Comments

This article is also available at https://www.nature.com/

Abstract

The intrinsic or mitochondrial apoptosis pathway is controlled by the interaction of antiapoptotic and pro-apoptotic members of the BCL-2 protein family. Activation of this death pathway plays a crucial role in cancer progression and chemotherapy responses. The BCL-2-related ovarian killer (BOK) possesses three BCL-2 homology domains and has been proposed to act in a similar pro-apoptotic pathway as the pro-apoptotic proteins BAX and BAK. In this study, we showed that stage II and III colorectal cancer patients possessed decreased levels of BOK protein in their tumours compared to matched normal tissue. BOK protein levels in tumours were also prognostic of clinical outcome but increased BOK protein levels surprisingly associated with earlier disease recurrence and reduced overall survival. We found no significant association of BOK protein tumour levels with ER stress markers GRP78 or GRP94 or with cleaved caspase-3. In contrast, BOK protein levels correlated with Calreticulin. These data indicate BOK as a prognostic marker in colorectal cancer and suggest that different activities of BOK may contribute to cancer progression and prognosis.

Disciplines

Physics | Physiology

Citation

Carberry S, D'Orsi B, Monsefi N, Salvucci M, Bacon O, Fay J, Rehm M, McNamara D, Kay EW, Prehn JHM. Cell Death & Disease. The BAX/BAK-like protein BOK is a prognostic marker in colorectal cancer. 2018;9(2):125

PubMed ID

29374142

DOI Link

10.1038/s41419-017-0140-2

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 4.0 License.

Share

COinS